New York Times rolls out new Web site health offerings

Share this article:

The New York Times recently expanded its NYTimes.com Web site offering to include a new section focused on consumer health and wellness issues.

NYTimes.com/Health officially rolled out at the beginning of this month and features original reports, scientific research, comprehensive licensed reference information, animations, videos, podcasts, slide-shows, Web-columns and interactive tools geared towards enabling readers to make informed health decisions.

“We really tried to design a site to help make patients smarter about their health,” Sarah Greene, product director, Health at NYTimes.com told MM&M. “The goal was to have good information pulled together, so you can get the big picture.”

Topics on NYTimes.com/health range from health maintenance issues to weight loss and exercise tips, to acute and chronic diseases, like cancer, diabetes and Alzheimer's disease.

New sections also include a blog from Tara Parker-Pope, long-time Wall Street Journal columnist who recently joined The Times to write a new blog called “Well,” focused on delivering practical advice on improving readers' health.

So far the blog has been "well"-received by readers, with an Oct. 2 posting on how marital spats can affect your health as one of the most e-mailed stories of the month.

The Times' new Web section has also been well-received by pharmaceutical sponsors, launching with six advertisers on board -- Sanofi-Aventis (Lantus), Boehringer Ingelheim (Mirapex), Merck (Zostavax and Januvia), Pfizer (Corporate), Wyeth (Enbrel) and Astra Zeneca (Symbicort).

Advertising opportunities available to pharma marketers include large ads, leader boards, half-page ads and sponsorship packages, The Times said.

As far as the future of the new Times health section is concerned, the sky's the limit, Greene says.
“We are focused on the best content. That's what we are all about.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...